Literature DB >> 19920188

EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.

Michelle Kinsey1, Richard Smith, Anita K Iyer, Edward R B McCabe, Stephen L Lessnick.   

Abstract

Most Ewing's sarcomas harbor chromosomal translocations that encode fusions between EWS and ETS family members. The most common fusion, EWS/FLI, consists of an EWSR1-derived strong transcriptional activation domain fused, in-frame, to the DNA-binding domain-containing portion of FLI1. EWS/FLI functions as an aberrant transcription factor to regulate genes that mediate the oncogenic phenotype of Ewing's sarcoma. One of these regulated genes, NR0B1, encodes a corepressor protein, and likely plays a transcriptional role in tumorigenesis. However, the genes that NR0B1 regulates and the transcription factors it interacts with in Ewing's sarcoma are largely unknown. We used transcriptional profiling and chromatin immunoprecipitation to identify genes that are regulated by NR0B1, and compared these data to similar data for EWS/FLI. Although the transcriptional profile overlapped as expected, we also found that the genome-wide localization of NR0B1 and EWS/FLI overlapped as well, suggesting that they regulate some genes coordinately. Further analysis revealed that NR0B1 and EWS/FLI physically interact. This protein-protein interaction is likely to be relevant for the development of Ewing's sarcoma because mutations in NR0B1 that disrupt the interaction have transcriptional consequences and also abrogate oncogenic transformation. Taken together, these data suggest that EWS/FLI and NR0B1 physically interact, coordinately modulate gene expression, and mediate the transformed phenotype of Ewing's sarcoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920188      PMCID: PMC2789197          DOI: 10.1158/0008-5472.CAN-09-1540

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.

Authors:  Michelle Kinsey; Richard Smith; Stephen L Lessnick
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

2.  A protein interaction network for pluripotency of embryonic stem cells.

Authors:  Jianlong Wang; Sridhar Rao; Jianlin Chu; Xiaohua Shen; Dana N Levasseur; Thorold W Theunissen; Stuart H Orkin
Journal:  Nature       Date:  2006-11-08       Impact factor: 49.962

3.  DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.

Authors:  E García-Aragoncillo; J Carrillo; E Lalli; N Agra; G Gómez-López; A Pestaña; J Alonso
Journal:  Oncogene       Date:  2008-06-30       Impact factor: 9.867

4.  Dax1 binds to Oct3/4 and inhibits its transcriptional activity in embryonic stem cells.

Authors:  Chuanhai Sun; Yuhki Nakatake; Tadayuki Akagi; Hiroki Ura; Takahiko Matsuda; Akira Nishiyama; Hiroshi Koide; Minoru S H Ko; Hitoshi Niwa; Takashi Yokota
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

5.  DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors.

Authors:  H Zhang; J S Thomsen; L Johansson; J A Gustafsson; E Treuter
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

6.  Dax-1 and steroid receptor RNA activator (SRA) function as transcriptional coactivators for steroidogenic factor 1 in steroidogenesis.

Authors:  Bin Xu; Wei-Hsiung Yang; Isabelle Gerin; Chang-Deng Hu; Gary D Hammer; Ronald J Koenig
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

7.  Microsatellites as EWS/FLI response elements in Ewing's sarcoma.

Authors:  Kunal Gangwal; Savita Sankar; Peter C Hollenhorst; Michelle Kinsey; Stephen C Haroldsen; Atul A Shah; Kenneth M Boucher; W Scott Watkins; Lynn B Jorde; Barbara J Graves; Stephen L Lessnick
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-14       Impact factor: 11.205

8.  An extended transcriptional network for pluripotency of embryonic stem cells.

Authors:  Jonghwan Kim; Jianlin Chu; Xiaohua Shen; Jianlong Wang; Stuart H Orkin
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

9.  The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.

Authors:  Noëlle Guillon; Franck Tirode; Valentina Boeva; Andrei Zynovyev; Emmanuel Barillot; Olivier Delattre
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

10.  EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.

Authors:  Leah A Owen; Ashley A Kowalewski; Stephen L Lessnick
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

View more
  49 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 2.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

Review 3.  The orphan nuclear receptors at their 25-year reunion.

Authors:  Shannon E Mullican; Joanna R Dispirito; Mitchell A Lazar
Journal:  J Mol Endocrinol       Date:  2013-11-26       Impact factor: 5.098

Review 4.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

5.  Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.

Authors:  Hyewon Park; Timothy K Turkalo; Kayla Nelson; Stephen Sai Folmsbee; Caroline Robb; Brittany Roper; Mizuki Azuma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

Review 7.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

Review 9.  Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Authors:  Stephen Safe; Un-Ho Jin; Erik Hedrick; Alexandra Reeder; Syng-Ook Lee
Journal:  Mol Endocrinol       Date:  2013-12-02

10.  Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Authors:  Christy L Osgood; Nichole Maloney; Christopher G Kidd; Susan Kitchen-Goosen; Laura Segars; Meti Gebregiorgis; Girma M Woldemichael; Min He; Savita Sankar; Stephen L Lessnick; Min Kang; Malcolm Smith; Lisa Turner; Zachary B Madaj; Mary E Winn; Luz-Elena Núñez; Javier González-Sabín; Lee J Helman; Francisco Morís; Patrick J Grohar
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.